Knight Therapeutics (TSE:GUD) Announces Earnings Results

Knight Therapeutics (TSE:GUD) issued its quarterly earnings data on Thursday. The company reported C($0.03) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of C$136.74 million during the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%.

Here are the key takeaways from Knight Therapeutics’ conference call:

• Knight reported record first-nine-month results, with revenue up 36% to CAD 430 million and adjusted EBITDA up 57% to more than CAD 76 million year over year. It raised 2026 guidance to CAD 560–570 million in revenue and adjusted EBITDA of approximately 17.5% of revenue.
• The company increased expected peak annual revenue from pipeline and launch products to more than CAD 300 million, up from more than CAD 200 million, citing stronger-than-expected product performance and the addition of Poteligeo. Most of the potential is attributed to products already approved, and 22 of more than 75 planned launches have been executed.
• Knight generated CAD 96 million in operating cash flow in the first nine months and ended the quarter with CAD 137 million in cash and marketable securities, a net cash position of CAD 115 million. Management said it expects strong EBITDA-to-cash-flow conversion to continue, though quarterly results may fluctuate.
• Generic and branded-generic versions of AmBisome were approved in Brazil, and Knight expects them to pressure AmBisome sales and adjusted EBITDA contribution beginning in 2027. The company is negotiating to retain most of the 2027 government contract, but expects generics to compete for later contracts as well.
• Management expects EBITDA margins to remain broadly consistent over the next couple of years as it continues investing in launches, with expansion possible as newer products contribute more. It noted that newer licensing agreements generally carry better gross margins than some legacy products.

Knight Therapeutics Stock Performance

GUD stock traded down C$0.14 during mid-day trading on Friday, hitting C$11.42. The company had a trading volume of 74,637 shares, compared to its average volume of 91,879. Knight Therapeutics has a 12 month low of C$5.66 and a 12 month high of C$11.86. The company has a debt-to-equity ratio of 4.29, a quick ratio of 1.79 and a current ratio of 2.28. The stock’s fifty day moving average price is C$10.60 and its two-hundred day moving average price is C$8.67. The firm has a market cap of C$1.12 billion, a PE ratio of 76.13, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.51.

Knight Therapeutics Company Profile

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.